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The relevance of different in vitro culture models of cancer cells is a hot topic, but few systematic and defin-
itive analyses in this area exist. In this issue of Cell Chemical Biology, Senkowski et al. (2016) address this
issue by studying the transcriptomic profiles of drug-treated cancer cells cultured in two-dimensional and
three-dimensional cultures. They describe biological findingswith potential therapeutic implications and pro-
vide a unique data resource to mine.The approach of using in vitro chemosen-
sitivity profiling of cancer cells as a means
to identify general and personalized can-
cer cell vulnerabilities has re-emerged as
a popular research subject, both because
it can complement and help us under-
stand and implement personalized cancer
cell genomics as well as because of
recent significant advances in cell culture
methodologies of primary and estab-
lished cultures of cancer cells (Friedman
et al., 2015). However, these approaches
have also been challenged due to prob-
lems in data reproducibility, lack of sta-
ndardized methods of following drug
responses and questions about which
cell culture models are relevant to use
(Hatzis et al., 2014).
In this context, it follows simple logic
that three-dimensional (3D) in vitro cul-
tures in many ways can be expected to
bemore biologically relevant than cultures
where cells are grown as monolayers on a
stiff flat (2D) surface, such as in a conven-
tional cell culture dish. The biological
advantages of 3D culture can often be
seenwhen cells that are cultured in proper
3D conditions form cellular morphological
structures that are also observed in vivo.
On the other hand, there are many strate-
gies and schools of thought onbiologically
relevant culturing of cells in three-di-
mensional arrangements, ranging from
spheroid non-adherent cultures, adher-
ence-supportive extracellular matrices,
growth on 3D scaffolds, to extremely
advanced organ-on-a-chip models. A
recent perspective by Horvath and co-
workers thoroughly describes many of
these key methodologies and how they
can be used (Horvath et al., 2016).
Still, 2D culture assays are simpler, less
costly, and typically more robust. There-
fore, an important question is what thecritical functional changes are between
the culture conditions and the biological
processes that may be relevant to study
in 2D versus 3D, and, if it is the latter,
what type of 3D culture is the most rele-
vant. However, surprisingly few compre-
hensive comparative studies between
monolayer and 3D culture conditions
exist; instead, 3D culture superiority is
often described with a near-religious
conviction by its proponents as unques-
tionable and unchallengeable (although
the type of 3D culture is not always spec-
ified). An additional challenge in under-
standing the role of cell culture conditions
is that chemosensitivity testing, and espe-
cially high-throughput analyses of drug
treatments, has most commonly been
done with simple bioassays, such as
those following overall cell viability, and
the depth of the biological responses re-
corded have therefore been limited. In
that sense, it is very clear that we need
to use more advanced assays to follow
drug responses and that these methods
need to be standardized so that the re-
sults from one laboratory can be com-
pared to the results from another.
With the vast amount of pre-existing in-
formation about transcriptomic profiles
from in vitro and in vivo settings, studying
transcriptomic responses in drug-treated
cancer cells can be a powerful way
of recognizing cellular responses and
perhaps their relevance. This approach
was first showcased in the seminal Con-
nectivity Map study, published a decade
agobyLambet al., 2006, inwhich the tran-
scriptomic changes of three cancer cell
lines when treated with over 1000 bioac-
tive compounds were studied with micro-
array technology. Even though the drug
treatments were done at a single dose,
which were not always the most physio-Cell Chemical Biology 23, Novlogically relevant, the data resource from
the Connectivity Map study has been
tremendously valuable for the research
community and countless follow-up
studies and analyses has been done by
others based on the dataset. While the
approach of using chip-based microarray
transcriptome analysis was limiting for
further broad scale analysis, new technol-
ogies that have since been developed
have opened the door for high-throughput
transcriptome profiling. The group behind
the Connectivity Map developed a
miniaturized Luminex bead-based meth-
odology in which the abundance of a
representative subset of mRNAs are
used to infer the full transcriptome called
L1000 (Duan et al., 2014). Multiplexed
next-generation RNA sequencing is
emerging as another feasible approach
(Moyerbrailean et al., 2015).
In this issue of Cell Chemical Biology,
Senkowski et al. (2016) provide the first
study of its kind in which compound-
induced transcriptomic changes in cells
grown in different 2- or 3D conditions
were explored. This work followed on a
previous study by the authors (Senkowski
et al., 2015) in which they performed one
of the first comprehensive bioactive com-
pound profiling campaigns comparing the
cell viability effects on adenocarcinoma
cells in monolayer growth versus a three-
dimensional spheroid growth condition in
which the cells were made quiescent by
nutrient deprivation (Karlsson et al., 2012).
Using this method, they discovered that
although the quiescent cell spheroids
generally had reduced sensitivity to cyto-
toxic chemotherapy, they also gained
sensitivity to inhibitors of oxidative phos-
phorylation, suggesting that generally
safe anti-helminthic drugs that tar-
get oxidative phosphorylation could beember 17, 2016 ª 2016 Elsevier Ltd. 1323
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current study, they explore the L1000
methodology to profile the transcriptomic
changes of cells grown either in 2D or in
3D spheroids that have been maintained
in either nutrient-rich or nutrient-depleted
media when treated with conventional
cytotoxic chemotherapyandwithoxidative
phosphorylation inhibitors. First, Senkow-
ski et al. (2016) show that the data gener-
ated is consistent with overlapping data
from the LINCS project (http://www.
lincsproject.org/) (Duan et al., 2014), high-
lighting that this approach is robust and
reproducible between laboratories. Sec-
ond, they discover that nutrient-deprived
quiescent spheroidal culture induces
mevalonate pathway gene expression,
suggesting an increased dependence
on cholesterol, and that oxidative phos-
phorylation inhibitors further enhance this
expressional pattern. In agreement with
these findings, HMG-CoA reductase inhib-
itors (statins) and other mevalonate meta-
bolism inhibitors are found to synergize
with the oxidative phosphorylation inhibi-
tors, showing the power of identifying1324 Cell Chemical Biology 23, November 17effective drug combinations through this
deep biological profiling and arguing for
further exploration of combinations of
oxidative phosphorylation inhibitors and
statins in cancer models. It is of interest
that many of the compounds identified
in the screens of quiescent spheroidal
cultures have also been identified in
screens against cancer stem cells, linking
the quiescent spheroidal cultures to
cholesterol metabolism and cancer cell
stemness.
Perhaps most importantly, this study
sets a new standard in biological profiling
of drug sensitivity testing in 3D cell cul-
ture. Furthermore, the transcriptomic
response data generated is expected to
become a very valuable resource for
further mining and generation of under-
standing of drug responses in different
cell culture conditions.
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